JAMA Neurology : Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease
Interview with Charbel Moussa, MD, PhD, author of Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"JAMA Network","authorlink":""},"src":"http:\/\/traffic.libsyn.com\/jamaneurologyauthorinterviews\/Nilotinib_Effects_on_Safety_Tolerability_and_Potential_Biomarkers_in_Parkinson_Disease.mp3","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202106\/970999-c85a-3176-06bf21_800.jpg"},"title":"JAMA Neurology : Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease","link":"javascript:;","id":"item-257735"}]
